Canakinumab

4 trials LOncology

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

0 Recruiting

4 Completed trials

3 Sponsors

8 Countries

Phase III

Phase II

Phase I (Other)

Phase III: 2 Phase II: 1 Phase I (Other): 1

Indications tested

Neoplasm malignant 1 Non-small cell lung cancer 1

Sponsors using this IMP

Novartis Pharma AG 2 IRCCS Istituto Giannina Gaslini 1 Universitaet Leipzig 1

All trials

4 total

A double-blind, placebo-controlled, randomized withdrawal study of canakinumab in pyogenic sterile arthritis pyoderma gangrenosum and acne (… Ended

2024-517155-13-00 Phase III 1 country IRCCS Istituto Giannina Gaslini
A Phase II, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Canakinumab for the Treatment of Anemia in Patients with IPSS-… Ended

2024-515886-33-00 Phase II 1 country Universitaet Leipzig
Rollover study for continued safety and tolerability in subjects treated with spartalizumab alone or in combination with other study treatme… Ended

2023-508841-42-00 Phase I (Other) 8 countries Novartis Pharma AG
Study of efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab in previously untreated l… Ended

2024-511490-29-00 Phase III 2 countries Novartis Pharma AG

Showing 1–4 of 4 trials

← All drugs A–Z